Myriad Genetics Puts Up $270M For Crescendo Bioscience

Law360, New York (February 5, 2014, 11:55 AM EST) -- Myriad Genetics Inc. announced Tuesday that it will acquire venture capital-backed Crescendo Bioscience Inc., a South San Francisco-based manufacturer of tests for inflammatory and autoimmune diseases such as rheumatoid arthritis, for $270 million in cash.

Salt Lake City, Utah-based Myriad said in a statement that the $270 million purchase price will be reduced by $25 million for the repayment of a loan made to Crescendo, a company that Myriad says will fit well into its diagnostic portfolio and diversify its overall business.

"Crescendo has pioneered protein-based...
To view the full article, register now.